comparemela.com

Latest Breaking News On - Lpg5201 - Page 1 : comparemela.com

Galapagos NV: Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress

All 7 out of 7 eligible patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter's Transformation (RT), responded to treatment (Objective Response Rate of 100%)1

Region flamandeMecklenburg vorpommernDaniel estbanSergi betriuJeevan shettyMarieke vermeerschSandra cauwenberghsNuria martinez cibrianVan gijselJulio delgadoChristian jacquesMercedes montoroStefan klotterValentin ortiz maldonadoLeticia alserawanMargotj pont

Galapagos NV: Galapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in rrCLL

All 7 out of 7 eligible patients with relapsed/refractory Chronic Lymphocytic Leukemia, with or without Richter's transformation, responded to treatment (Objective Response Rate of 100%)GLPG5201 showed

Region flamandeJulio delgadoMercedes montoroLeticia alserawanValentin ortiz maldonadoChristian jacquesSchwierige zeitenPaul stoffelsVan gijselSandra cauwenberghsNuria martinez cibrianMarieke vermeerschMargotj pontDaniel estbanSergi betriuElisa chenailler

vimarsana © 2020. All Rights Reserved.